FindTrial
Sign In

The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy

The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy - The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022151
Enrollment
5
Registered
2016-04-30
Start date
2016-04-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy

Interventions

mefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manths

Sponsors

Department of Neurology, Shimane University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Less than six months after PML onset. 2) JC virus positive in cerebrospinal fluid. 3) Patients who can provide consent to participate in this study by themselves or their representative. 4) 20 years old or older at the time of an agreement

Exclusion criteria

Exclusion criteria: 1) Patients with other infection of the central nervous system. 2) Physical status is severe or unstable. 3) Patients with severe psychiatric disorder. 4) Pregnant women or patients with possible pregnancy. 5) Patients with a history of hypersensitivity to this drug.

Design outcomes

Primary

MeasureTime frame
Survival time and an improvement in KPS and MMSE at baseline and 6 months thereafter.—

Countries

Japan

Contacts

Public ContactChizuko Hamada

Shimane University Hospital Department of Neurology

okuzihc.@med.shimane-u.ac.jp0853-20-2195

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026